Skip to main content

Medicus Pharma Ltd.

corporate_fare Company Profile

Medicus Pharma Ltd.

MDCX·NASDAQ·Life Sciences·CIK 0001997296

Medicus Pharma Ltd. was incorporated on April 30, 2008, in Ontario, Canada, initially as Interactive Capital Partners Corporation. On September 29, 2023, the company completed a business combination with SkinJect Inc., a Pennsylvania-based company, which resulted in SkinJect becoming a wholly owned operating subsidiary and the company being renamed Medicus Pharma Ltd. This transaction was a reverse takeover by SkinJect's former shareholders. The company's common shares began trading on the TSX Venture Exchange under the symbol "MDCX" on October 11, 2023. On November 15, 2024, Medicus Pharma Ltd. completed its initial public offering in the United States, and its common shares and public warrants, with an exercise price of $4.64 and an expiration date of November 15, 2029, commenced trading on Nasdaq under the symbols "MDCX" and "MDCXW," respectively. The company's common shares were voluntarily delisted from the TSXV on February 21, 2025, but continue to be listed on Nasdaq. On August 29, 2025, Medicus Pharma Ltd. acquired 98.6% of the issued and outstanding shares of Antev for approximately US$2.97 million in cash and 1,603,164 common shares of Medicus.

Medicus Pharma Ltd. (NASDAQ:MDCX) is a publicly traded company in the Life Sciences sector. Wiseek monitors MDCX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Medicus Pharma Secures $3.85M Through Equity Sales, Prepaying Debt
  • Medicus Pharma Discloses $3.85M Equity Sale, Resulting in Significant Dilution
  • Medicus Pharma's Skin Cancer Drug Achieves 73% Clinical Clearance in Positive Phase 2 Trial
  • Institutional Investor Registers 4.02M Shares for Resale, Adding Significant Market Overhang
  • Medicus Pharma Launches $15.3M At-The-Market Offering, Signaling Critical Need for Capital Amidst Going Concern Warning

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$47.28M
Diluted EPS
-$2.74
Op. Cash Flow
-$22.78M
Operating Income
-$34.36M
Cash & Equivalents
$8.71M
Total Debt
$5.25M
Debt / Equity
-77.65×
Shares Outstanding
25.18M sh
Source: 10-K · filed 2026-04-29 · accession 0001062993-26-002212
$0.34 +0.00% today
52-week range · as of 2026-06-04 $0.25 – $3.69
Market cap
$19.13M
Volume
946.4K (0.4× avg)
3-mo avg 2.5M
Live data · 2026-06-12 21:16 UTC · After hours

show_chartPrice Chart

Loading chart...

feed MDCX - Filings & News (Page 2)

MDCX
Mar 06, 2026, 4:57 PM EST
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.3816
Real-time Price: $0.340 info
Change: -$0.0416 (-11%) info
Market Cap: $19.133M info
MDCX
Mar 06, 2026, 4:40 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3843
Real-time Price: $0.340 info
Change: -$0.0443 (-12%) info
Market Cap: $19.133M info
MDCX
Mar 05, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.30
Real-time Price: $0.340 info
Change: -$0.960 (-74%) info
Market Cap: $19.133M info
MDCX
Jan 30, 2026, 4:31 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.19
Real-time Price: $0.340 info
Change: -$0.850 (-71%) info
Market Cap: $19.133M info
MDCX
Jan 02, 2026, 10:26 AM EST
Filing Type: 424B5
Importance Score:
9
Price at Filing: $1.60
Real-time Price: $0.340 info
Change: -$1.26 (-79%) info
Market Cap: $19.133M info